Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Cellectis SA (ZVA) Stock Price & Analysis

ZVA Stock Chart & Stats

€1.03-€0.05(-4.46%)
At close: 5:30 PM GMT+1
EUR 1EUR 1.5EUR 2EUR 2.520 Aug22 Sep2 Oct20 Oct
Day’s Range
EUR 1.03 - EUR 1.03
52-Week Range
EUR 0.88 - EUR 4.65
Previous Close
EUR 1.08
Volume
0
Average Volume (3M)
446
Market Cap
EUR 75.07M
Enterprise Value
EUR 205.35M
Total Cash (Recent Filing)
EUR 166.85M
Total Debt (Recent Filing)
EUR 84.57M
Price to Earnings (P/E)
―
Beta
0.32
Next Earnings
Nov 09, 2026 (Est.)
EPS Estimate
-0.16
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Allogeneic Therapy Platform

An allogeneic, off-the-shelf approach could support broader and more scalable cell-therapy delivery than individualized treatments if clinical development succeeds. The combination of engineered T-cell research and associated manufacturing capabilities gives Cellectis an integrated platform for advancing multiple therapeutic programs.

Solid Gross Margins

A historically healthy gross margin indicates that the underlying technology, collaboration, or service activities can generate substantial value relative to direct costs. If revenue expands through partnerships or successful programs, this margin profile could provide operating leverage once development spending becomes better supported by revenue.

Demonstrated Cash-generation Potential

Positive operating and free cash flow in 2024 shows that Cellectis has previously been able to convert its activities into cash rather than relying exclusively on external funding. Although cash generation has since reverted to negative, this history indicates potential for improvement if collaboration receipts or operating performance strengthen.

Bears Say

Revenue Contraction

Declining TTM revenue weakens the near-term foundation for funding research and clinical development, particularly because Cellectis has limited recurring product sales and relies heavily on collaboration-related economics. Revenue volatility also makes it harder to plan investment and assess the pace at which the business can scale.

Deep Operating Losses

The scale of current losses shows that gross profit is not yet sufficient to absorb Cellectis's operating and development cost base. Persistently negative EBIT and EBITDA reduce internal funding capacity and make future financial performance highly dependent on successful clinical progress, partnerships, or eventual commercialization.

Cash Burn And Weaker Equity Cushion

Large ongoing cash burn combined with a reduced equity cushion limits financial flexibility while the company remains clinical-stage. Higher debt relative to equity can increase pressure on future capital allocation and funding decisions, leaving less capacity to absorb delays or sustain development investment without additional financing.

Cellectis SA News

ZVA FAQ

What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €0.88 and its highest was €4.65 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €75.07M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s next earnings report is estimated for Nov 09, 2026 (not yet confirmed), which is in 7 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 06, 2026. The company reported -€0.19 earnings per share for the quarter, beating the consensus estimate of -€0.227 by €0.037.
Is Cellectis SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.16.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.19 in its last earnings report, beating expectations of -€0.227. Following the earnings report the stock price went down -7.717%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in DE:ZVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology